Abstract
Background: Denosumab is a human monoclonal antibody that binds to receptor activator of nuclear factor kappa-B ligand (RANKL). This inhibits the binding of RANKL to RANK on osteoclasts which reduces the activity of osteoclasts and avoids bone loss, and thus increases bone density. In addition, recent studies also showed that Denosumab seems to suppress blood sugar, but the underline mechanism is still unknown. Interestingly, some studies revealed the glucose-lowering effects by Denosumab may be related to the protection of β cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
